Questioning labeling issues seems quite hypothetical and doesn’t seem like a strong reason for delay. If the question is simple and MHRA responds within a day or two, would Northwest then raise another issue just to extend the timeline?
Also, if approval comes tomorrow and the stock moves to $1 or higher, they wouldn’t need to dilute 50 million shares to raise funds—they could achieve the same with far fewer shares, maybe 10 million or less. More importantly, time is very valuable, and they could use the next three weeks for post-approval preparations.
In my opinion, this whole assumption doesn’t really add up.
Market Data 
Markets 
AI
